Advances in Cancer Research: Targeting the RAS Oncoprotein

Advances in Cancer Research, volume 153, provides a comprehensive review of the biology, biochemistry, and current therapeutic approaches to target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. The successful approval and use of the first direct RAS inhibitor (sotorasib) in 2021 for treating non-small cell lung cancers with KRAS(G12C) mutations has highlighted that the once undruggable RAS is indeed pharmacologically tractable.

This volume offers an in-depth overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. It also includes excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.

History and Development of RAS Inhibition

The history and development of efforts to pharmacologically inhibit RAS are thoroughly discussed, providing insights into the challenges and successes in this field.

Biochemistry and Biology of RAS Mutants

Detailed discussions on the biochemistry and biology of different RAS mutant proteins are included, highlighting how these differences might be effectively leveraged in the development of anti-RAS therapies.

Cutting-Edge Approaches to Anti-RAS Therapies

Up-to-date reviews of the latest approaches to develop new anti-RAS pharmacologics are presented, showcasing the ongoing research and innovation in this area.

Published by Elsevier Science on January 29, 2022, this volume is a valuable resource for researchers, scientists, and healthcare professionals interested in understanding the complexities of RAS and its role in cancer.